Delving into the Latest Updates on WA-8242-A1 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

WA-8242-A1, WA8242A1

Target

PLA2

Action

inhibitors

Mechanism

PLA2 inhibitors(Phospholipases A2 inhibitors)

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Inflammation

Originator Organization

Fujisawa Pharmaceutical Co., Ltd.

Active Organization-

Inactive Organization

Fujisawa Pharmaceutical Co., Ltd.

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

WA8242A1, A2 and B, novel inhibitors of secretory phospholipase A2 (PLA2), were obtained from Streptomyces violaceusniger No. 8242. WA8242B inhibited secretory group I and II PLA2s in a dose-dependent manner. The mode of inhibition of group II PLA2 by WA8242B was in competitive fashion. WA8242B inhibited group II PLA2-induced Prostaglandin I2 (PGI2) production by human umbilical vein endothelial cells. Furthermore, WA8242B was effective in mouse zymosan writhing model.

01 Jan 1998·The Journal of antibioticsQ4 · MEDICINE

WA8242A1, A2 and B, Novel Secretary Phospholipase A2 Inhibitors Produced by Streptomyces violaeeusniger. III. Structure Elucidation and Total Synthesis of WA8242B.

Q4 · MEDICINE

Article

Author: Otsuka, Takanao ; Hemmi, Keiji ; Takase, Shigehiro ; Okada, Satoshi ; Yoshimura, Seiji ; Okamoto, Masanori

The structure of WA8242B, a potent novel inhibitor against phospholipase A2, was fully characterized by spectroscopic methods and chemical degradation. The success of total synthesis of WA8242B confirmed the structure and allowed the pharmacological study of WA8242B. The structures of WA8242A1 and A2 were also described.

100 Deals associated with WA-8242-A1

Login to view more data